Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04522362 · ClinicalTrials.gov registry record · NA
Modeling Stress-precipitated Vaping Behavior
A NA study, sponsored by Clemson University.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT04522362: Completed NA study, sponsored by Clemson University.
NCT04522362 is a NA study that has completed, run by Clemson University. The registered enrollment target is 51 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04522362, a NA study, has completed, sponsored by Clemson University.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
The primary aims of this pilot study were to (1) initially validate the applicability of a human laboratory model of relapse initially developed for smokers to e-cigarette users; (2) to use this human laboratory model of lapse behavior to examine the effects of acute psychological stress on vaping-lapse behavior among adults who are experienced, e-cigarette users.
Primary Outcome
Time to vaping during the vaping delay task. Range of time delay is 0 minutes to 50 minutes.
Interventions
- OTHER Control task and Trier Social Stress Task
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2018-06-30 |
| Phase | NA |
What the finished NCT04522362 record still lists
NCT04522362 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Control task and Trier Social Stress Task is the first listed.
NCT04522362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04522362 about?
NCT04522362 is a clinical study titled "Modeling Stress-precipitated Vaping Behavior". The primary aims of this pilot study were to (1) initially validate the applicability of a human laboratory model of relapse initially developed for smokers to e-cigarette users; (2) to use this human laboratory model of lapse behavior to examine the effects of acute psychological stress on vaping-l...
What is the current status of trial NCT04522362?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2017-10-25. Estimated completion is 2018-06-30.
What interventions are being tested in trial NCT04522362?
The interventions under investigation include: Control task and Trier Social Stress Task (OTHER).
Who is sponsoring clinical trial NCT04522362?
This trial is sponsored by Clemson University, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04522362's enrollment target sits among peer trials
51 1279th of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI